IDEXX LaboratoriesFRA:IX1 -0.19%96 PB Ratio is 27.89 as of Jun. 25, 2026, which is 56% below its 10-year median of 63.32. GuruFocus rates FRA:IX1 with a GF Score™ of 96/100 and a GF Value™ of €544.17 (Modestly Undervalued). Among 196 Medical Diagnostics & Research companies, IDEXX Laboratories ranks worse than 96.94% on this metric.
IDEXX Laboratories Inc stock PB Ratio (=27.96) is close to 1-year low of 26.93.
The historical rank and industry rank for IDEXX Laboratories's PB Ratio or its related term are showing as below:
FRA:IX1'
s PB Ratio Range Over the Past 10 Years
Min: 20.9 Med: 63.32 Max: 459.65
Current: 27.96
During the past 13 years, IDEXX Laboratories's highest PB Ratio was 459.65. The lowest was 20.90. And the median was 63.32.
FRA:IX1's PB Ratio is ranked worse than 96.94% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.05
vs FRA:IX1: 27.96
During the past 12 months, IDEXX Laboratories's average Book Value Per Share Growth Rate was 9.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 40.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 27.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of IDEXX Laboratories was 52.40% per year. The lowest was -36.70% per year. And the median was 10.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
IDEXX Laboratories PB Ratio Related Terms
IDEXX Laboratories PB Ratio Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, IDEXX Laboratories's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's PB Ratio distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
IDEXX Laboratories (FRA:IX1) has a PB Ratio of 27.89 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on IDEXX Laboratories and its competitors. This is 56% below median its historical median of 63.32. Over the past decade, IDEXX Laboratories' PB Ratio has ranged from 20.90 to 459.65. According to the industry distribution chart, IDEXX Laboratories ranks #190 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 96.9%.
Is IDEXX Laboratories' PB Ratio too high?
IDEXX Laboratories' current PB Ratio of 27.89 is 56% below median its 10-year median of 63.32. Over the past 10 years, this metric has ranged from a low of 20.90 to a high of 459.65. The Medical Diagnostics & Research industry median PB Ratio is 2.05. IDEXX Laboratories' value of 27.89 is 1260.5% above this industry median. Based on the distribution chart, IDEXX Laboratories ranks #190 out of 196 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' PB Ratio compare to A and WAT?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #190 out of 196 companies for PB Ratio. This places IDEXX Laboratories in the lower half of its industry. The industry median PB Ratio is 2.05. IDEXX Laboratories' value of 27.89 is 1260.5% above this benchmark. Historically, IDEXX Laboratories' own PB Ratio has ranged from 20.90 to 459.65 over the past decade. While the company's 10-year median is 63.32 vs. the industry median of 2.05, IDEXX Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.05, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEXX Laboratories's current PB Ratio of 27.89 is 1260.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on IDEXX Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current PB Ratio is 27.89, which is 56% below median its own 10-year median of 63.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €544.17, compared to a current price of €473.80 — trading 12.9% below its estimated fair value. The current PB Ratio is 27.89, which is 56% below median its 10-year median of 63.32 and 1260.5% above the Medical Diagnostics & Research industry median of 2.05. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current PB Ratio is 27.89 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €473.80 is trading 12.9% below its estimated GF Value™ of €544.17.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:IX1:
PB Ratio: 27.89 (56% below median its 10-year median of 63.32)
GF Value™: €544.17 vs. price of €473.80 (12.9% below fair value)
Industry Position: 1260.5% above the Medical Diagnostics & Research median (#190 of 196)
No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for FRA:IX1
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IX1 has been successfully added to your 
